Forte Biosciences ($FBRX) Stock Hub: argenx Completes the $77 Cash Acquisition, FBRX Delisted

01 argenx has acquired Forte Biosciences for $77 per share in cash

argenx and Forte Biosciences signed a definitive agreement on July 26, 2026 under which argenx would acquire all outstanding $FBRX shares for $77.00 per share in cash. Both boards approved it, the offer carried no financing condition, and argenx funded it from cash on hand. The closing 8-K puts the total cost of the transaction, including the payments for options, restricted stock units and pre-funded warrants, at approximately $2.2 billion, all of it from argenx’s own cash.

The announced price represents an approximately 41% premium to Forte’s July 24 closing price of $54.78 and, according to the companies, an approximately 86% premium to FBRX’s volume-weighted average price since the July 9 vitiligo data. The announcement guided to a close in Q3 2026, subject to the tender of at least a majority of the outstanding shares and to expiration or termination of the U.S. antitrust waiting period. Both conditions were met, and the merger became effective on August 27, 2026, inside that window.

That process is now finished. $FBRX ceased trading before the opening of business on August 27, the merger became effective the same day, and the Nasdaq filed the Form 25 notification of removal from listing and registration. What is left on this page is the record of a company that was bought, not the analysis of a security anyone can still trade.

02 Latest confirmed update — August 28, 2026

July 26 and 27, 2026: Forte signed the merger agreement with argenx on July 26 and the two companies announced it on July 27. The terms are $77 per share in cash, valuing the company at approximately $2.2 billion. The transaction will proceed through a cash tender offer followed by a merger and is expected to close in Q3 2026, subject to customary conditions.

The acquisition converted the FBRX setup from a standalone clinical-stage biotech thesis into a fixed-price transaction, and the transaction has now been paid. FB102 remains the scientific reason argenx bought the company, and it continues inside argenx; the listed security does not. Everything below that describes ownership, float, runway and catalysts is the record of what Forte looked like on the day it was acquired, with each figure carrying its own reference date.

03 Main watch item

Nothing on this security, and one procedural item on the filing docket. The offer, the minimum condition, the antitrust clearance and the closing are all settled. The Form 15 that terminates registration under Section 12(g) had been announced but not filed when this page was verified. Everything else worth watching about FB102 is now disclosed by argenx.

04 Core thesis

argenx is paying to add FB102’s anti-CD122 biology and multi-indication potential to its immunology portfolio after Forte produced positive early data in celiac disease and vitiligo.

05 Main risk

The completion risk that dominated this file for a month is gone: the merger became effective on August 27, 2026. What is left is narrow and procedural. Holders who properly perfected appraisal demands under Section 262 of the DGCL sit outside the $77.00 conversion and are handled under that statute. Everyone else is owed $77.00 per share in cash, payable promptly after the expiration date.

06 How the closing is documented

Three documents record the closing, and they agree with one another. The Form 8-K filed by Forte on August 27, 2026 at 4:15 p.m. Eastern carries Items 2.01, 3.01, 3.03, 5.01, 5.02 and 5.03. Amendment No. 3 to the Schedule TO, filed by Avena Merger Sub, argenx BV and argenx SE at 9:27 a.m. the same morning, reports the expiration and the tender result. The argenx SE press release of August 27 at 8:50 a.m. Eastern, filed as Exhibit (a)(5)(vi) to that amendment, announces the completion. The tender figure, 19,894,879 shares and approximately 87.13%, is identical in all three.

The July 26 merger filing requires more than 50% of outstanding shares to be validly tendered, plus satisfaction or waiver of the other offer conditions, including the Hart-Scott-Rodino waiting period. The outside date is November 30, 2026, and Forte may owe a $65 million termination fee in specified circumstances. The offer documents were filed on August 6, 2026: a Schedule TO by Avena Merger Sub and argenx, and a Schedule 14D-9 in which the Forte board unanimously recommends that holders tender their shares. The second-step merger would follow under Section 251(h) of the Delaware General Corporation Law, without a shareholder vote. Forte merger 8-K · Pre-commencement Schedule TO communication.

What happened between August 18 and August 27

What the closing documents say, item by item. The offer expired one minute after 11:59 p.m. Eastern on August 26 and was not extended. Computershare, depositary and paying agent, advised that 19,894,879 shares had been validly tendered and not validly withdrawn; together with the shares argenx and its affiliates already owned, that is approximately 87.13% of the shares then outstanding, comfortably above the threshold of one share more than 50%. All other conditions were satisfied or waived. Purchaser irrevocably accepted the tendered shares for payment and will pay for them promptly. The merger followed the same day under Section 251(h) of the DGCL, so no meeting and no vote of Forte shareholders took place.

Where the 87.13% comes from, and why it does not divide into the cover-page share count. The offer to purchase discloses that argenx already held 951,655 shares, approximately 4.48% of the outstanding stock at August 5, 2026, bought for $25.0 million in the April 2026 follow-on at $26.27 per share. Add those to the 19,894,879 tendered and the numerator is 20,846,534. Divide that by the 21,229,087 shares on the Form 10-Q cover page and the answer is 98.2%, not 87.13%, so the two figures are measured against different bases. The reason is that the minimum condition is defined against the shares outstanding immediately following the consummation of the offer, and the cover-page count excludes the 3,956,842 pre-funded warrants outstanding at June 30, 2026, which the company reports separately and which are exercisable at any time for nominal consideration. Merlintrader reconstruction, not a disclosed figure: an 87.13% result on a numerator of 20,846,534 implies a denominator of roughly 23.9 million shares, which sits between the 21.23 million of common stock and the 25.19 million that common stock plus all pre-funded warrants would give. The closing documents do not publish that denominator, and this page does not invent one.

What holders of the other instruments receive. Each option with an exercise price below $77.00 was cancelled and converted into a lump-sum cash payment equal to the difference multiplied by the shares under the option, subject to withholding. Each option with an exercise price equal to or above $77.00 was cancelled with no payment. Each restricted stock unit was cancelled and converted into a cash payment of $77.00 per underlying share. Holders of pre-funded warrants outstanding at the offer acceptance time keep the right to receive $77.00 for each share issuable on exercise, without regard to the exercise limitations in the warrant agreement.

Who runs the company now. All eight directors in office immediately before the effective time — Paul A. Wagner, Steven Kornfeld, Scott Brun, Barbara K. Finck, Stephen K. Doberstein, Richard Vincent, Shiv Kapoor and David Gryska — ceased to be directors, and every officer ceased to hold office. The directors and officers of Avena Merger Sub, namely Arjen Lemmen, Karl Gubitz and Hemamalini (Malini) Moorthy, took their place, and the certificate of incorporation and the bylaws were amended and restated in full.

What remains to happen on the SEC side. The Form 25 filed by Nasdaq removes the shares from listing and from registration under Section 12(b). Forte states in the same 8-K that it intends to file a Form 15 to terminate registration under Section 12(g) and suspend its reporting obligations under Sections 13 and 15(d). Until that Form 15 appears on the docket, the deregistration is announced rather than completed.

The supplemental disclosure of August 21, and why nine letters arrived

Amendment No. 2 to the Schedule 14D-9 states that since the original filing of August 6 the company received nine demand letters from purported holders, each alleging that the Schedule 14D-9 omitted material information and demanding corrective disclosure. Forte states it believes the claims are without merit, that as of August 21 it was not aware of any lawsuit filed against the transaction, and that it specifically denies any additional disclosure was required. This is the standard pattern in United States public deals: letters arrive, the target supplements without conceding, and the supplement itself removes the argument.

The supplemental figures are the interesting part, because they show the valuation work behind the $77.00.

• The projections. Management prepared unaudited forecasts for fiscal years 2026 through 2045, with risk-based adjustments, approved by the board for Guggenheim Securities to rely on. They were not provided to argenx.
• The discounted cash flow. A discount rate range of 11.75 to 14.50 per cent, the mid-year convention, and a valuation date of June 30, 2026. Terminal value used a perpetual growth rate of negative 50 per cent, reflecting the assumed global loss of exclusivity for FB102 in 2043. Tax expense assumed a 25 per cent rate and roughly $153 million of cash savings from tax assets in fiscal 2032 through 2034.
• The share count used. 20.49 million basic shares at July 24, 2026, plus the dilutive impact of options, restricted stock units, pre-funded warrants and employee purchase plan rights under the treasury stock method.
• The premium checks. Guggenheim reviewed thirteen precedent clinical-stage biopharma transactions since 2025 with enterprise values above $1 billion. The 25th to 75th percentile of one-day unaffected premia, 42 to 79 per cent, applied to the unaffected price of $54.78, gives $77.79 to $98.06 per share. The same percentiles of premia to 52-week highs, 13 to 48 per cent, applied to the $59.70 high, give $67.46 to $88.36. The offer price of $77.00 sits at or just below the bottom of the first range and inside the second.
• The analyst targets. Five Wall Street price targets published before the unaffected date ranged from $54.00 to $75.00, against the $77.00 offer.
• The adviser fee. Guggenheim’s transaction fee is currently estimated at approximately $43 million payable on consummation, against $2.0 million that became payable on delivery of the opinion and is credited against it.

Read together, those figures describe a price negotiated at the low end of the precedent premium range on the unaffected price and above every published analyst target. Both statements are true at once, and which one carries more weight depends on whether the unaffected price or the sell-side view is treated as the fairer benchmark. That is a judgment, and the disclosure exists so shareholders can make it themselves.

Forte after the closing

Forte Biosciences is no longer an independently traded company and $FBRX is no longer a tradable symbol. The scientific content on FB102 keeps its usefulness, because the asset continues inside argenx and its readouts still matter to anyone following anti-CD122 biology. The parts of this page that describe a listed security — the ownership split, the float, the runway, the sentiment and the catalyst map — are historical as of August 27, 2026. They are kept here as the record of what the company looked like on the day it was bought, each with its reference date, not as a description of anything that can be traded today.

07 Executive Summary

The Forte Biosciences equity story changed decisively at the end of July 2026. argenx and Forte entered into a definitive agreement on July 26, announced on July 27 to acquire Forte for $77 per share in cash, representing approximately $2.2 billion in total equity value. Both boards approved the transaction, argenx funded it from cash on hand, and the deal was completed on August 27, 2026, inside the Q3 window the companies had guided to.

The announced consideration represents an approximately 41% premium to Forte’s $54.78 closing price on July 24. The companies used a second reference point in the official announcement: the $77 price represents an approximately 86% premium to FBRX’s volume-weighted average price since Forte reported positive Phase 1b vitiligo data on July 9. Those two percentages measure different baselines and should not be confused.

The strategic logic is FB102. Forte’s proprietary anti-CD122 monoclonal antibody produced positive Phase 1b celiac disease data in June 2025 and statistically significant, placebo-controlled Phase 1b vitiligo data in July 2026. argenx believes that FB102 may have “pipeline-in-a-product” potential across celiac disease, vitiligo, alopecia areata and other autoimmune conditions. The buyer had already made a strategic investment in Forte through the April 2026 financing, so the acquisition is an escalation of an existing relationship rather than a completely new approach.

For the four weeks the offer was open, the analytical framework was merger arbitrage rather than the Phase 2 celiac readout, and every one of its questions has now been answered. The offer commenced on August 6 and expired on schedule on August 26 without an extension. The Hart-Scott-Rodino waiting period expired on August 18. Roughly 87% of the stock was in argenx’s hands at the expiration, no competing proposal ever appeared, and untendered shares were converted into the right to receive the same $77.00 cash consideration in the second-step merger.

The record below is kept complete on purpose. The clinical and financial background explains what argenx paid for, the transaction sections explain how the price was set and tested, and the sentiment section shows how the market handled a deal it treated as near-certain. None of it describes a security that can still be bought or sold.

08 Fast Facts

09 Why $FBRX Matters Now

$FBRX matters as the record of a fixed-price cash transaction that ran from signature to completion in thirty-two days. argenx commenced the tender offer for all outstanding Forte shares at $77.00 each on August 6, 2026, the minimum condition and every other condition were satisfied, and on August 27 the second-step merger converted the shares that had not been tendered into the right to receive the same cash consideration.

The July 9 vitiligo data remain central to understanding why the buyer acted. FB102 had already produced positive Phase 1b celiac disease data in 2025. The vitiligo result added a second randomized, placebo-controlled signal, supporting the idea that CD122 biology may translate across autoimmune diseases. In the acquisition announcement, argenx explicitly cited the celiac and vitiligo studies as key drivers of its decision to move from strategic investment to full acquisition.

The market never had to price that question independently for long. The transaction completed on August 27, 2026 and crystallized $77.00 per share in cash. No superior proposal was ever disclosed, and no delay or termination materialized. Whether the price argenx paid was full or cheap will be settled by the Phase 2 celiac readout, which is now argenx’s to report.

Key framing after the closing: Forte was a clinical-stage autoimmune company built around FB102, and FB102 is now an argenx asset. Clinical developments still matter, to argenx’s return rather than to a Forte share price, because that share price stopped existing on August 27, 2026.

10 Company Overview

Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. Its development story is centered on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate. The company is headquartered in Dallas, Texas and traded on Nasdaq under the symbol FBRX until August 27, 2026. Under the merger agreement signed on July 26 and announced on July 27, Forte became a wholly owned subsidiary of argenx on completion of the tender offer and the second-step merger.

For investors, the most important historical point is that Forte has already gone through a major reset. The company previously developed FB-401 for atopic dermatitis. In September 2021, Forte announced that FB-401 failed to meet the primary endpoint in a Phase 2 trial. That failure reshaped the company and makes execution history relevant when evaluating the current FB102 story.

The current Forte is therefore not the same clinical narrative that existed before FB102 became the lead asset. The company became more focused and more concentrated, allowing a single program to drive a sharp revaluation after positive data. argenx’s $2.2 billion agreement validates the strategic importance of that program, although it does not remove the procedural risk that exists until the transaction closes.

11 FB102 and the CD122 Thesis

FB102 is designed to target CD122, the beta subunit shared by IL-2 and IL-15 receptor signaling. Forte’s thesis is that this pathway sits upstream of disease-relevant immune activity across multiple autoimmune conditions. The company has described FB102 as a way to modulate pathogenic T-cell and NK-cell biology while attempting to avoid overly broad immune disruption.

The appeal of this approach is easy to understand. Celiac disease, vitiligo and alopecia areata are different clinical diseases, but each involves immune-mediated tissue damage. In celiac disease, gluten exposure triggers immune injury in the small intestine. In vitiligo, autoimmune activity contributes to melanocyte destruction and depigmentation. In alopecia areata, immune attack targets hair follicles. Forte is trying to connect these diseases through a common immunologic axis.

The scientific risk is also clear. A mechanism that looks coherent across diseases does not automatically translate into broad clinical success. Each indication has its own endpoint, patient population, placebo behavior, regulatory standard, competitive bar and commercial reality. FB102 must prove itself disease by disease.

Simple translation: the market is watching whether FB102 is merely an interesting antibody with early signals, or whether it can become a repeatable autoimmune drug-development platform.

12 Pipeline and Indication Map

13 Celiac Disease: The Central Scientific Validation Program

Celiac disease was the most important standalone FBRX catalyst before the acquisition agreement and remains a central part of FB102’s strategic value to argenx. Forte initiated a Phase 2 celiac disease study after reporting positive Phase 1b data in June 2025. Company updates in 2026 continued to point to a Phase 2 readout in the second half of 2026, and the July 27 acquisition announcement reiterated that timing.

The earlier Phase 1b celiac study enrolled 32 subjects randomized 3:1 to FB102 or placebo. Subjects received four doses of FB102 at 10 mg/kg and underwent a 16-day gluten challenge. The study assessed safety and tolerability, morphologic and inflammatory endpoints, and gluten-challenge-induced symptoms.

The key data were encouraging. Forte reported a statistically significant benefit on the composite histological VCIEL endpoint, with placebo subjects showing a mean VCIEL change from baseline of -1.849 compared with 0.079 for FB102-treated subjects, producing a p-value of 0.0099. The company also reported that intraepithelial lymphocyte density increased by 13.3 in placebo subjects but declined by 1.5 in FB102-treated subjects, with a p-value of 0.0035.

Symptom data also leaned in the right direction. Forte reported that gluten-challenge-induced gastrointestinal symptom events occurred at 4.0 events per subject in the FB102 arm versus 6.9 events per subject in the placebo arm, representing a 42% benefit. The trial had no dropouts, and treatment-emergent adverse events were primarily Grade 1, with no Grade 3 or higher serious adverse events reported in the FB102 arm.

The Phase 2 trial is the real test because celiac disease is not an easy development category. Gluten-free diet remains the foundation of treatment, but accidental exposure and persistent symptoms create a real unmet-need narrative. A drug that can protect intestinal histology, reduce immune activation and improve symptoms could attract meaningful attention. But the clinical and regulatory bar is not trivial. Endpoints must be interpretable, effects must be clinically meaningful, and safety must be acceptable for a chronic disease population.

Celiac readout logic after the deal: a positive Phase 2 result would strengthen the scientific rationale for argenx’s acquisition and its pipeline-in-a-product thesis. A weak or mixed result now bears on the value of FB102 inside argenx. It cannot touch the $77.00 that Forte holders were paid, which was fixed by contract and settled at the closing.

14 Vitiligo: The July 2026 Data That Preceded the Acquisition

Vitiligo is the update that turned Forte from a celiac-only story into a company two buyers could argue about. On July 9, 2026, Forte announced positive results from the FB102 double-blind, placebo-controlled Phase 1b study in non-segmental vitiligo. The study enrolled 43 subjects randomized 3:1, with 32 receiving FB102 and 11 receiving placebo.

The primary endpoint was mean percent improvement from baseline in Facial Vitiligo Area Scoring Index, or FVASI, assessed by central review. In the protocol-defined efficacy-evaluable population, which included 32 FB102-treated subjects and 10 placebo subjects, FB102 achieved a 29.6% mean FVASI improvement from baseline at Week 24 versus 7.9% for placebo. That produced a placebo-adjusted FB102 benefit of 21.7% and a p-value of 0.020.

The intent-to-treat analysis looked even more separated because placebo worsened. Forte reported that in the ITT population, FB102 improved by 29.6% from baseline while placebo deteriorated by 16.2%, producing a placebo-adjusted benefit of 45.8% and a p-value of 0.005. The difference between the ITT and protocol-defined analyses is important because a single placebo subject with facial hair and substantial progression was excluded from the protocol-defined efficacy-evaluable population.

The subgroup with baseline FVASI of at least 0.75 was especially notable. Forte reported that in subjects with greater disease involvement, FB102 achieved a 43.2% mean FVASI improvement from baseline at Week 24 compared with 0.5% for placebo, producing a placebo-adjusted benefit of 42.7% and a p-value of 0.006. In that subgroup, 10 of 17 FB102-treated subjects achieved FVASI50, or 58.8%, and 4 of 17 achieved FVASI75, or 23.5%. No placebo subject in that subgroup achieved FVASI50 or FVASI75.

Durability after the dosing period is another part of the signal. Forte said response to FB102 was observed early, with statistically significant improvement by Day 64, and continued through Week 24 after completion of the 12-week treatment period. The company reported that subjects continued improving between Week 12 and Week 24, with an additional eight percentage-point mean FVASI improvement overall and a fourteen percentage-point improvement in subjects with baseline FVASI of at least 0.75.

The safety description was also supportive for an early trial. Forte reported a favorable safety profile compared with placebo and said adverse events were mild to moderate. That language is particularly important in vitiligo because any systemic immunomodulatory therapy must clear a high tolerability bar, especially when an approved topical therapy already exists.

The competitive context cannot be ignored. The FDA approved Opzelura, ruxolitinib cream, for non-segmental vitiligo in adult and pediatric patients 12 years and older in 2022. That means any future FB102 vitiligo program under argenx must eventually show why a systemic anti-CD122 antibody deserves a place in a market where topical JAK inhibition is already available. Possible differentiation could come from patient selection, durability, response depth, systemic disease biology or specific populations, but those points remain unproven until larger trials are designed and reported.

15 Alopecia Areata: Logical Extension, Harder Competitive Bar

Alopecia areata fits Forte’s immune-biology thesis because the disease involves immune-mediated attack on hair follicles. Forte has guided for a Phase 1b alopecia areata readout in 2026. If positive, this could provide a third clinical signal for FB102 and strengthen the argument that CD122 modulation has repeatable relevance across autoimmune dermatology and gastrointestinal disease.

However, alopecia areata is not an empty field. The therapeutic landscape has already changed significantly with approved JAK inhibitor options. This matters because investors should not treat every positive early autoimmune signal as commercially equal. A future FB102 alopecia signal would need to be viewed against existing therapies, safety expectations, speed of response, durability and patient-selection strategy.

For this file, alopecia areata was scientific optionality inside the transaction rationale rather than a public-market valuation pillar, and the $77.00 consideration settled the equity outcome. Celiac disease, vitiligo and alopecia together explain why argenx paid what it paid.

16 Financial Position, Cash Runway and Burn

The figures in this section describe Forte as it stood at June 30, 2026, the last balance-sheet date it reported as an independent public company. argenx funded the $77-per-share purchase entirely from its own cash on hand, approximately $2.2 billion in all, and Forte’s clinical spending is now part of argenx. The cash, burn and runway numbers below are kept because they explain what argenx acquired and what it no longer has to fund from an equity market, not because they still describe a company that has to raise money on its own.

Forte reported $49.6 million in cash and cash equivalents plus $148.8 million in short-term investments at June 30, 2026, which the company presents together as $198.5 million. Current assets were $203.1 million, total assets were $205.7 million, current liabilities were $20.3 million, total liabilities were $21.9 million and shareholders’ equity was $183.8 million. The company reported no product revenue, which is normal for a clinical-stage biotech but important for risk framing.

Operating expenses stayed high through the second quarter. Research and development expense was $22.2 million in Q2 2026 and $42.5 million for the first half, against $20.3 million in Q1. The company attributes the level of spending to the Phase 2 celiac disease trial and the Phase 1b trials in vitiligo and alopecia areata, plus preclinical and personnel costs. General and administrative expense was $2.3 million in Q2 and $4.2 million for the first half. The net loss was $23.3 million in Q2 and $45.5 million for the first half, or $0.97 and $2.18 per share. Operating cash use was $41.5 million over the six months.

The April 2026 public offering materially changed the capital picture. Forte priced 5,709,936 common shares at $26.27 per share, with an underwriters’ option for up to 856,490 additional shares. The 424B5 filing shows total public offering proceeds of approximately $172.5 million with the over-allotment option, underwriting discounts and commissions of approximately $10.35 million, and proceeds before expenses to Forte of approximately $162.15 million.

The Q2 10-Q replaces the earlier editorial bridge with a reported figure: $198.5 million of cash and short-term investments at June 30, 2026, after the April proceeds and after $41.5 million of operating cash use in the first half. Forte therefore entered the tender period with a funded balance sheet, which matters mainly to the scenario in which the transaction does not close.

Positive financial read-through

The April raise reduced immediate financing pressure and allowed Forte to negotiate from a stronger balance-sheet position. The signed acquisition is not subject to a financing condition and will be funded from argenx’s cash on hand.

Remaining financial risk

Forte remains pre-commercial until closing. If the deal is delayed or terminated, larger trials, regulatory work and indication expansion would again make burn rate and future dilution central to standalone valuation.

17 Dilution, Share Count and Capital Structure

Dilution is central to the $FBRX story. Forte reported 13.9 million common shares and 4.0 million pre-funded warrants outstanding at March 31, 2026. After the April 2026 offering the count rose to 20,482,400 common shares at June 30, 2026, and to 21,229,087 as of August 7, 2026 on the cover of the Q2 10-Q. Approximately 4.43 million securities were excluded from the diluted loss per share calculation for the first half because they were anti-dilutive.

The April offering was strategically useful because it strengthened the balance sheet before major readouts. But it also expanded the share count. That trade-off is common in biotech: companies often raise when data or expectations allow them to finance at better levels, and investors then have to decide whether the added runway offsets the dilution.

The fully diluted picture is more complex than the basic share count. Forte has pre-funded warrants, options, restricted stock units and shares reserved under equity incentive plans. The company has also used shelf registration capacity, and future financing flexibility remains part of the capital structure. Shelf capacity does not mean an immediate raise, but it is part of the normal funding toolkit for a clinical-stage biotech.

The merger settled all of it. Every outstanding common share was purchased in the offer or converted into the right to receive $77.00 in cash, options in the money were cashed out at the spread, options at or above the price were cancelled for nothing, restricted stock units were cashed out at $77.00 per underlying share, and pre-funded warrant holders kept the right to $77.00 for each share issuable on exercise. Standalone dilution stopped being a question on August 27, 2026.

18 Management and Execution Profile

Until the effective time on August 27, 2026, Forte was led by Paul Wagner, Ph.D., as CEO and chairman. The leadership team also includes finance, operations and clinical-development executives with biotechnology and drug-development backgrounds. For a company at this stage, the key execution questions are not branding or commercial scale; they are trial design, enrollment, regulatory alignment, manufacturing readiness and capital allocation.

Execution history should be treated with balance. Forte’s prior FB-401 program failed its Phase 2 atopic dermatitis endpoint in 2021, which is a legitimate reminder that early promise can fail in controlled trials. But FB102 is a different asset and a different mechanism. The current evidence should therefore be judged on FB102’s own clinical data, while still remembering that the company has already experienced a major clinical reset.

The last execution test this management team faced was the transaction itself, and it was passed: signed on July 26, offer commenced August 6, antitrust cleared August 18, expiration met on August 26 with roughly 87% tendered, merger effective August 27. All eight directors and every officer left office at the effective time. The Phase 2 celiac readout remains a major scientific milestone for the second half of 2026, and it is now argenx’s to deliver.

19 Timeline of Key Developments

September 2021Forte announced that FB-401 failed to meet statistical significance in a Phase 2 atopic dermatitis trial, setting the stage for a later strategic reset.
June 23, 2025Forte announced positive Phase 1b data for FB102 in celiac disease, including statistically significant histological and inflammatory endpoint results after gluten challenge.
Second half of 2025The company continued advancing FB102 and framed 2026 as a multi-readout year across celiac disease, vitiligo and alopecia areata.
March 31, 2026Forte reported 2025 results and reiterated expected 2026 clinical readouts for FB102.
April 2026Forte priced and completed a major public offering, materially strengthening its cash position ahead of clinical catalysts.
May 11, 2026Forte reported Q1 2026 results, disclosed $58.2 million in cash at March 31, highlighted FDA Fast Track Designation for FB102 in celiac disease and pointed to important FB102 readouts.
July 9, 2026Forte announced positive Phase 1b vitiligo data for FB102, including statistically significant FVASI improvement at Week 24.
July 26 and 27, 2026Forte signed the merger agreement with argenx on July 26 and the two companies announced it on July 27: $77.00 per share in cash, approximately $2.2 billion of total equity value.
August 6, 2026argenx and Avena Merger Sub commenced the cash tender offer at $77.00 per share, with an expiration set for August 26, 2026; the Forte board recommended acceptance in its Schedule 14D-9.
August 12, 2026Forte filed its Q2 2026 Form 10-Q, reporting $198.5 million of cash and short-term investments at June 30 and a first-half net loss of $45.5 million.
August 18, 2026The Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern, satisfying the antitrust condition; both parties had filed their premerger notification on August 3.
August 21, 2026Amendment No. 2 to the Schedule 14D-9 added the supplemental disclosure on the projections, the discounted cash flow assumptions and the nine demand letters received since August 6.
August 26, 2026Last trading day at a close of $76.99, one cent below the offer price; the offer expired one minute after 11:59 p.m. Eastern and was not extended, with 19,894,879 shares validly tendered and not withdrawn.
August 27, 2026argenx announced the completion at 8:50 a.m. Eastern, Nasdaq filed the Form 25-NSE, and Forte filed the closing Form 8-K recording the merger under Section 251(h) of the DGCL. Forte survives as a wholly owned subsidiary of argenx and $FBRX is no longer traded.
Still expected inside argenxPhase 2 celiac disease topline data remain the major FB102 scientific milestone, and alopecia areata Phase 1b data were guided for 2026 by Forte before the acquisition. Any future disclosure on those programs will come from argenx, not from a Forte filing.

20 Forward Catalyst Map

21 What the outcome was

Three scenarios were open while the offer ran. Each is set against what the documents ended up showing.

The path that was taken

The transaction closed cleanly and on the announced schedule: the offer expired as scheduled on August 26 without an extension, the minimum condition was met with a wide margin at approximately 87.13%, and the merger became effective the next day. The last regular close of $76.99 on August 26, one cent below the consideration, is what a spread looks like when the market treats completion as close to certain, and the market was right.

The paths that were not taken

The upside case required a formally disclosed superior proposal or an agreed increase in the consideration. Neither appeared at any point between the July 27 announcement and the closing, so $77.00 remained the contractual price throughout. The downside case was a delay or a termination: a failed minimum-tender condition, a regulatory obstacle or a contractual dispute. None occurred. The HSR waiting period expired on August 18 without a second request, and the nine demand letters recorded on August 21 produced no lawsuit that Forte was aware of as of that date.

What remains scientifically open

The Phase 2 celiac disease data and the alopecia areata Phase 1b data are still scientifically important, and they now sit inside argenx. They no longer have a price attached to them on any exchange, because the security that carried that price no longer exists. Anyone tracking FB102 from here follows argenx disclosures.

22 Red Flags and Monitoring Checklist

23 Retail Sentiment and Trading Psychology

While the offer was open, $FBRX attracted two different trading groups: biotech investors focused on FB102 and merger-arbitrage traders focused on the spread to $77. Their frameworks were not identical. A biotech trader speculated about celiac data or a competing bidder; an arbitrage investor watched closing probability, regulatory timing and the annualized return implied by the spread. The arbitrage side had the better of the argument, and the last close a cent below the offer price is the measure of it.

Social-media discussion framed $77 alternately as a guaranteed floor and as an opening bid. Neither description was correct while the offer was open: not a floor, because the deal had not closed, and not an opening bid, because no superior proposal was ever disclosed. In the end $77.00 was simply the price, and it was paid. What follows is how retail positioning looked around a deal that closed exactly as written.

This hub does not use unverified Reddit, Stocktwits or X/Twitter posts as factual evidence. For $FBRX, the controlling sources are the merger agreement, Schedule TO, Schedule 14D-9, SEC amendments, antitrust disclosures and official closing communications.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

24 Bottom Line

argenx has acquired Forte Biosciences for $77.00 per share in cash. The transaction was completed on August 27, 2026, thirty-two days after the merger agreement was signed, at a total cost of approximately $2.2 billion funded entirely from argenx cash. It is a substantial strategic validation of FB102 and of the early clinical signals Forte produced in celiac disease and vitiligo.

The process ran without a complication worth the name. The antitrust condition cleared on August 18, the offer expired on schedule on August 26 with roughly 87% of the stock in hand, no competing bidder ever appeared, and the second-step merger followed the next day under Section 251(h), which is the mechanism that lets a deal of this shape close without a shareholder meeting. Nasdaq filed the Form 25 the same day. The one item left on the SEC side is the Form 15, which Forte has said it intends to file and which had not appeared on the docket when this page was verified on August 28, 2026.

What that leaves for a reader is a record rather than a position. $FBRX is not a symbol anyone can trade, the float and the runway figures on this page describe a company that no longer sets its own course, and the clinical questions that made Forte interesting now belong to argenx. FB102 keeps its scientific interest as an anti-CD122 antibody argenx describes as potentially first-in-class, with proof of concept in vitiligo and celiac disease; the Phase 2 celiac readout is still the number that decides whether the price argenx paid looks cheap or full. That readout will be disclosed by argenx, and what is left here is the account of what was bought and on what terms.